UAEM - Licensing and patenting practices of UK research institutions 2019-2020

Sarai Keestra made this Freedom of Information request to University of Nottingham

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

The request was successful.

Dear University of Nottingham,

We have previously sent FOI requests asking for information about the licensing practices of UK universities. This was concerning the time period 18th October 2018 to 18th October 2019. We are now looking to update the information for the following year, 19th October 2019 to 19th October 2020.

The updated request is listed below:
For the purpose of clarity, please adhere to the following definitions when answering these questions:

Definitions
Low and middle income country: A country that is defined as ‘low’, ‘lower-middle’ and ‘upper-middle’ income by the World Bank for the year 2018. Income status defined by GNI per capita.
Source: World bank, available online [https://tinyurl.com/y5dwc2qv]

A patent grants an inventor the exclusive rights to his or her invention. A patent holder can stop other people from selling, manufacturing, producing, or using the invention for a certain period of time.
Source: Upcouncil, available online [https://www.upcounsel.com/what-is-a-pate...
Licence: Permission for the licensee to use the intellectual property rights
Source: TaylorWessing, available online [https://www.taylorwessing.com/download/a...

Exclusive Licence: A licence that allows only the named licensee to exploit the relevant IP rights, the licensor is also excluded from exploiting these IP rights.
Non-Exclusive Licence: A licence that grants any number of licensees to exploit the IP.
Source: TaylorWessing, available online [https://www.taylorwessing.com/synapse/co...

Health Technology: ‘Health technology as defined by the WHO: “A health technology is the application of organized knowledge and skills in the form of devices, medicines, vaccines, procedures and systems developed to solve a health problem and improve quality of lives.’
Source: WHO, available online [https://www.who.int/health-technology-as...

START FOI request:
Q1. Has the university committed to licensing its medical discoveries in ways that promote access and affordability in Low- and Middle- Income Countries? If yes, please provide a link or PDF to the relevant policy document.

Q2. Please provide an Excel spreadsheet with headings as displayed below with all the health technologies LICENSED by the university in the period 19th October 2019 to 19th October 2020 AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses.
Health Technology Licensed | Country of Licensing | Type of License (Exclusive or Non-Exclusive)

Q3. Please provide a list of patents granted to your organization in the period 19th October 2019 to 19th October 2020, listed by patent family, indicating countries/regions in which the patent has been granted.

Q4. In the period 19th October 2019 to 19th October 2020, has the university shared its best practices for promoting access to medicines through non-exclusive licensing by carrying out any of the following activities?

❏ Contributed sample clauses to the AUTM Global Health Toolkit
❏ Published an article, guidance, or other literature on access licensing practices
❏ Formally presented on access licensing practices at an academic or professional event, or at another university
❏ Informally shared or discussed access licensing practices with administrators at other universities
❏ Other
❏ None
(Tick as appropriate)

Q5. What actions has the technology transfer office (TTO) undertaken in the period 19th October 2019 to 19th October 2020 to improve access to the technologies they license in low-and middle-income settings?

END FOI request.
If you have any questions please do not hesitate to contact me by email.

Yours faithfully,

Sarai Keestra

Br-Freedom-Of-Information, University of Nottingham

Dear Sarai

Thank you for your request for information regarding licensing and patenting practices of UK universities. Your request was received on 10 November 2020 and is being dealt with under the terms of the Freedom of Information Act 2000. The reference number of your request is 4065.

We will aim to respond to your request within twenty working days. Please note this is calculated from the following working day from receipt of your request.

Please be aware that due to the Covid-19 pandemic, and following Government advice, the University is moving to online teaching and staff are working remotely, this may mean that access to some information held locally or on certain systems may not be readily available at this time.

Where it becomes clear that the information you have requested is not available due to the current situation, we will of course write to you and advise you of this.

I hope that this is of help. Please do not hesitate to contact me if you have any enquiries regarding this email.

Yours sincerely,
Karen Page

Information Compliance Officer – Freedom of Information
Registrar’s Department

Web: www.nottingham.ac.uk/freedom-of-informat...
Email: [University of Nottingham request email]

show quoted sections

Br-Freedom-Of-Information, University of Nottingham

3 Attachments

Dear Sarai

I am writing further to your request for information regarding licensing and patenting practices of UK universities. A search of our electronic and paper records has been completed.

In answer to your request:

Q1. Has the university committed to licensing its medical discoveries in ways that promote access and affordability in Low- and Middle- Income Countries? If yes, please provide a link or PDF to the relevant policy document.

No such document is held by the University.

Q2. Please provide an Excel spreadsheet with headings as displayed below with all the health technologies LICENSED by the university in the period 19th October 2019 to 19th October 2020 AND specify which countries they were licensed in AND specify whether they are exclusive or non-exclusive licenses.

Please see attached spreadsheet.

Q3. Please provide a list of patents granted to your organization in the period 19th October 2019 to 19th October 2020, listed by patent family, indicating countries/regions in which the patent has been granted.

Please see attached spreadsheet.

Q4. In the period 19th October 2019 to 19th October 2020, has the university shared its best practices for promoting access to medicines through non-exclusive licensing by carrying out any of the following activities?

❏ Contributed sample clauses to the AUTM Global Health Toolkit ❏ Published an article, guidance, or other literature on access licensing practices ❏ Formally presented on access licensing practices at an academic or professional event, or at another university ❏ Informally shared or discussed access licensing practices with administrators at other universities ❏ Other

None of the above.

Q5. What actions has the technology transfer office (TTO) undertaken in the period 19th October 2019 to 19th October 2020 to improve access to the technologies they license in low-and middle-income settings?

We have not licensed any technologies to low or middle income countries during this period.

If you are unhappy with the way in which your request has been handled and wish to request a review of our response or to make a complaint, please see the attached information sheet and form.

Please do not hesitate to contact me if you have any enquiries regarding this email.

Yours sincerely,
Karen Page

Information Compliance Officer – Freedom of Information
Registrar’s Department

Web: www.nottingham.ac.uk/freedom-of-informat...
Email: [University of Nottingham request email]

show quoted sections